Skip to content
JCP
PCC
News
CME
About
Authors
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors
Sign In
Subscribe
Clinical Topics
View All
Depression
Neurologic
Anxiety
Schizophrenia
Trauma
Psychopharmacology
Bipolar
Tardive Dyskinesia
OCD
Addiction
View All
Columns
View All
ASCP Corner
Clinical & Practical Psychopharmacology
Rounds General Hospital
Academic Highlights
Banner Alzheimer’s Institute
Focus on Geriatric Psychiatry
Hanna Putkonen, MD, PhD
JCP
Original Research
Substance Induced Schizophrenia
January 15, 2013
Read a study investigating the rate of SIP conversion to schizophrenia spectrum disorder.
Jussi A. Niemi-Pynttärin
,
Reijo Sund
,
Hanna Putkonen
, et al
JCP
Original Research
Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity: A 16-Week Open-Label Extension Phase and Both Phases of a Randomized Controlled Trial
August 24, 2010
Evgueni Tchoukhine
,
Pirjo Takala
,
Helinä Hakko
, et al
JCP
Original Research
Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity: A 16-Week Randomized, Double-Blind, Placebo-Controlled Trial
May 11, 2008
Grigori Joffe
,
Pirjo Takala
,
Evgueni Tchoukhine
, et al
JCP
Original Research
Topiramate Add-On in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
August 15, 2005
Jari Tiihonen
,
Pirjo Halonen
,
Kristian Wahlbeck
, et al
